cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Clinical trial NCT04842565 · COMPLETED

Trial details

NCT number: NCT04842565
Sponsor: Fudan University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2021-05-01
Primary completion: 2022-05-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.